Beware of the Bots: Pharmaceutical Astroturfing in the ADHD Space

About this episode

Something happened overnight. Jonathan Murphy, PMHNP-BC, posted a podcast episode about generic ADHD medications and the pharmaceutical narratives behind them. Within hours, two comments arrived on two different YouTube videos defending two different pharmaceutical positions. One defended brand-name drugs. The other defended guanfacine. Both arrived the same night. Both escalated when challenged. Neither could answer a direct question. This episode covers what happened in those comment threads in real time, why the phrase “comparative RCT” is not something a YouTube viewer says, why a commenter who has never taken guanfacine argued for it across ten comments using pharmaceutical vocabulary, what happened when the question “are you on Takeda’s payroll” was asked and not answered three times, and what the SEC filings reveal about Takeda’s financial incentive to expand guanfacine into the adult ADHD market. Also covered: Amy Arnsten and Yale receiving royalties from Takeda on every Intuniv prescription, the ADHD Institute as a Takeda-funded educational platform, the $220 million annual revenue growing 105% year over year, the government alignment between pharmaceutical companies wan